Please enable JavaScript.
Coggle requires JavaScript to display documents.
dipeptidyl peptidase IV inhibitors-saxagliptin (contraindications (liver…
dipeptidyl peptidase IV inhibitors-saxagliptin
indications
improve glycemic control in patients with type 2 diabetes
mechanism of action
inhibit degradation of endogenous incretins which increases insulin secretion
decreases glucagon secretion
side effects
tachycardia
headache, dizziness
easy bleeding or bruises
painful urination
hoerseness
severe nausea and vommiting
contraindications
liver failure
moderate to severe renal failure
diabetic ketoacidasis
heartfailure
diarrhoea
pancreatitis
arthralgia
route of administration
2.5 to 5 mg once daily oral taken with or without food
storage
store at 4 degrees cecius
store at -20 degrees celcius fr long term